Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2006 1
2007 1
2009 1
2011 3
2013 1
2014 1
2015 2
2019 1
2020 2
2021 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.
Nicosia L, Spencer GJ, Brooks N, Amaral FMR, Basma NJ, Chadwick JA, Revell B, Wingelhofer B, Maiques-Diaz A, Sinclair O, Camera F, Ciceri F, Wiseman DH, Pegg N, West W, Knurowski T, Frese K, Clegg K, Campbell VL, Cavet J, Copland M, Searle E, Somervaille TCP. Nicosia L, et al. Among authors: cavet j. Cancer Cell. 2023 Dec 11;41(12):2136-2153.e13. doi: 10.1016/j.ccell.2023.11.001. Epub 2023 Nov 22. Cancer Cell. 2023. PMID: 37995682 Free article.
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C. van Rhee F, et al. Among authors: cavet j. Lancet Oncol. 2014 Aug;15(9):966-74. doi: 10.1016/S1470-2045(14)70319-5. Epub 2014 Jul 17. Lancet Oncol. 2014. PMID: 25042199 Clinical Trial.
Predicting outcome in hematological stem cell transplantation.
Dickinson AM, Cavet J, Cullup H, Wang XN, Jarvis M, Sviland L, Middleton PG. Dickinson AM, et al. Among authors: cavet j. Arch Immunol Ther Exp (Warsz). 2002;50(6):371-8. Arch Immunol Ther Exp (Warsz). 2002. PMID: 12546063 Review.
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.
Schey S, Brown SR, Tillotson AL, Yong K, Williams C, Davies F, Morgan G, Cavenagh J, Cook G, Cook M, Orti G, Morris C, Sherratt D, Flanagan L, Gregory W, Cavet J; Myeloma UK Early Phase Clinical Trial Network. Schey S, et al. Among authors: cavet j. Br J Haematol. 2015 Aug;170(3):336-48. doi: 10.1111/bjh.13435. Epub 2015 Apr 20. Br J Haematol. 2015. PMID: 25891006 Free article. Clinical Trial.
15 results